Skin Cancer And Radiotherapy Review

Dr. Jordan Stosky, MD, FRCPC

Radiation Oncology Preparatory Course

December 2, 2020

Disclosures

- I am not paid by ‘big melanoma’
  - Only ’big AHS’
- No outside funding to disclose

We have 1 hour

- What this is:
  - A basic science and anatomy refresher as it pertains to skin cancer and radiotherapy
  - An overview of *some* of the literature supporting and guiding treatment decisions in the use of radiotherapy in skin cancers
- What this is not:
  - A complete review of systemic agents and their use in skin cancers
    - Eg immunotherapy, targeted therapies
  - An exhaustive treatment planning compendium

Objectives

01

Review UV Radiobiology

02

Review Melanoma and Radiotherapy

03

Review BCC and SCC and Radiotherapy

04

Review Merkel Cell Carcinoma and Radiotherapy

05

Anatomy Refresher



UV carcinogenesis

UV Radiation is:



A) IONIZING

B) NON-IONIZING

UV Spectrum


X rays
Deeper penetration
UVC
UVB
UVA
100-280
280-310
310-400
Visible
Superficial penetration

UV radiation – chemical reaction

- >=10 eV or λ <=125nm is ionizing ('far' ultraviolet)
- Most UV radiation non ionizing (UV B)
- Forms pyrimidine dimers (T-T) which are cytotoxic
- UVB thought to be the cause of melanoma and other skin cancers
- UVA cause skin cancers and premature aging of skin

Table 27.3 Lesions Produced for a Given Level of Cell Killing by Various Cytotoxic Agents

AGENT	D_{37}	DNA LESION	NUMBER OF LESIONS PER CELL PER D_{37}
X-rays	1 Gy	SSB	1,000
		DSB	40
Bleomycin	5.5 μg × 1 h	SSB	150
		DSB	30
Ultraviolet light	10 J/m^2	TT dimer	1,000,000
		SSB	100
Benzopyrene	–	Adduct	100,000

SSB, single-strand break; DSB, double-strand break; TT, thymine-thymine.
Courtesy of Dr. John Ward, University of California, San Francisco.

UV Carcinogenesis




I
II
III
IV
V
VI
Pigmentary phototype
(Fitzpatrick scale)
Epidermal Melanin
UV phenotype
UV sensitive,
Burn rather than tan
UV resistant,
Tan; never burn
Cancer risk

Skin types



Melanoma

Always on your differential diagnosis

Table 1: Projected estimates of new cases and age-standardized incidence rates for cancers in Canada in 2020, by sex

	No. of new cases			ASIR*		
Type of cancer	Total†	Males	Females	In both sexes	Males	Females
All cancers‡	225 800	115 800	110 000	519.4	557.8	491.2
Lung and bronchus	29 800	15 000	14 800	61.4	64.8	59.3
Breast	27 700	240	27 400	66.9	1.1	128.2
Colorectal	26 900	14 900	12 000	60.5	71.5	50.8
Prostate	23 300	23 300	NA	NA	116.7	NA
Bladder§	12 200	9400	2800	25.0	42.0	10.7
Non-Hodgkin lymphoma	10 400	5800	4500	24.4	29.3	20.2
Thyroid	8600	2300	6400	22.5	11.7	33.1
Melanoma	8000	4400	3600	21.8	25.2	19.2
Kidney and renal pelvis	7500	4900	2600	17.3	23.6	11.5
Uterus (body, NOS)	7400	NA	7400	NA	NA	35.0
Leukemia	6900	4100	2800	16.5	21.1	12.6
Pancreas	6000	3100	2900	13.0	14.2	11.8
Oral	5400	3700	1650	12.8	18.5	7.5
Stomach	4200	2700	1450	9.4	13.1	6.1
Multiple myeloma	3400	2000	1450	7.8	9.7	6.1
Ovary	3100	NA	3100	NA	NA	14.2
Liver	3100	2300	810	6.8	10.6	3.3
Brain/CNS	3000	1700	1350	7.1	8.3	5.9
Esophagus	2400	1850	550	5.7	9.3	2.4
Cervix	1350	NA	1350	NA	NA	7.1
Testis	1150	1150	NA	NA	6.5	NA
Larynx	1150	980	180	2.3	4.1	0.7
Hodgkin lymphoma	1000	570	440	2.6	2.9	2.3
All other cancers	21 800	11 300	10 500	47.5	53.2	43.2

Note: ASIR = age-standardized incidence rate, CNS = central nervous system, NOS = not otherwise specified, NA = not applicable.
*Rates exclude those from Quebec.
†Column total may not sum to row totals owing to rounding.
‡All cancers excludes nonmelanoma skin cancers (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
§Bladder cancer includes in situ carcinomas.

Table 2: Projected estimates of deaths and age-standardized mortality rates for cancers in Canada in 2020, by sex

	No. of deaths			ASMR		
Type of cancer	Total*	Males	Females	Both sexes	Males	Females
All cancers	83 300	44 100	39 300	188	219.7	164.2
Lung and bronchus	21 200	11 000	10 200	47.2	53.4	42.5
Colorectal	9700	5300	4400	21.8	26.4	18.0
Pancreas	5300	2700	2600	12.0	13.5	10.7
Breast	5100	55	5100	11.9	0.3	22.0
Prostate	4200	4200	NA	NA	21.8	NA
Leukemia	3000	1800	1250	6.9	9.0	5.2
Non-Hodgkin lymphoma	2900	1600	1250	6.5	8.1	5.1
Bladder	2600	1850	720	5.7	9.6	2.8
Brain/CNS	2500	1400	1050	5.8	7.1	4.7
Esophagus	2300	1750	510	5.1	8.6	2.1
Ovary	1950	NA	1950	NA	NA	8.3
Stomach	1950	1200	760	4.5	6.0	3.2
Kidney and renal pelvis	1950	1300	680	4.4	6.4	2.8
Multiple myeloma	1600	880	700	3.5	4.4	2.8
Oral	1500	1050	440	3.5	5.3	1.8
Liver†	1450	1150	290	3.2	5.5	1.2
Uterus (body, NOS)	1300	NA	1300	NA	NA	5.4
Melanoma	1300	870	450	3.1	4.4	2.0
Cervix	410	NA	410	NA	NA	2.0
Larynx	400	330	75	0.9	1.6	0.3
Thyroid	230	110	130	0.5	0.5	0.5
Hodgkin lymphoma	100	65	40	0.2	0.3	0.2
Testis	35	35	NA	NA	0.2	NA
All other cancers	10 400	5400	5000	23.5	27.3	20.5

Note: ASMR = age-standardized mortality rate, CNS = central nervous system, ICD-10 = *International Statistical Classification of Diseases and Related Health Problems, 10th Revision*, NA = not applicable, NOS = not otherwise specified.
*Column total may not sum to row totals owing to rounding.
†Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9) were excluded.

Summary of projected number of cancer cases and deaths in Alberta (AB) in 2020*

Cancer	Males		Females		Both sexes	
	Cases	Deaths	Cases	Deaths	Cases	Deaths
All cancers	**11,200**	**3,800**	**10,100**	**3,400**	**21,300**	**7,200**
Prostate	3,000	440	N/A	N/A	3000	440
Breast	15	5	2,800	480	2,815	485
Colorectal	1,450	460	1,100	330	2,550	790
Lung and bronchus (lung)	1,150	850	1,250	890	2,400	1,740
Bladder	800	160	220	55	1,020	215
Non-Hodgkin lymphoma	520	130	390	95	910	225
Melanoma	390	70	350	45	740	115
Uterus (body, NOS)	N/A	N/A	750	110	750	110
Leukemia	440	140	290	100	730	240
Kidney and renal pelvis	480	110	230	55	710	165
Thyroid	200	15	500	10	700	25
Pancreas	280	240	270	250	550	490
Oral	360	80	140	35	500	115
Brain/CNS	170	140	130	90	300	230
Multiple myeloma	190	75	110	60	300	135
Stomach	190	95	110	65	300	160
Esophagus	240	210	50	50	290	260
Liver	190	100	75	30	265	130
Ovary	N/A	N/A	240	170	240	170
Cervical	N/A	N/A	170	40	170	40
Testis	160	5	N/A	N/A	160	5
Hodgkin lymphoma	70	5	40	5	110	10
Larynx	75	35	10	5	85	40

Melanoma Risk factors

- UVB
  - Greatest increase in RR in people who experience blistering sunburns
- Fair complexion
- Numerous benign or larger atypical nevi (>5mm)
  - 15% of melanomas are from melanocytic nevi
  - <10% are from non cutaneous sites. Commonly:
    - Mucosal
    - Uveal
    - Gyne areas
- Personal hx (HR 900)
- Family hx

Don’t forget your ABCDEs



Melanoma Genetics

- 10% familial with mutations in:
  - CDKN2A
  - CDK4
  - XP
  - BRCA2
- Familial atypical multiple mole-melanoma syndrome (FAMMM)
- CDKN2A mutation in >70% of lesions
- BRAF mutations
  - Younger, male patients
  - Tends to be more aggressive
  - 40-60% in advance disease

Normal Skin histology



Clark's levels

1. Confined to epidermis (in situ)
2. Invasion into papillary dermis
3. Invasion to junction of papillary and reticular dermis
4. Invasion into reticular dermis
5. Invasion into subcutaneous fat

Staging and Prognosis

N Category	Number of tumor-involved regional lymph nodes	Presence of in-transit, satellite and/or microsatellite metastases	T Category								
			T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
			No evidence of primary tumor	<0.8 mm without ulceration	<0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration	>1.0-2.0 mm without ulceration	>1.0-2.0 mm with ulceration	>2.0-4.0 mm without ulceration	>2.0-4.0 mm with ulceration	>4.0 mm without ulceration	>4.0 mm with ulceration
N0	No regional metastases detected	No	-	IA	IA	IB	IIA	IIA	IIB	IIB	IIC
N1a	1 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N1b	1 clinically detected	No	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N1c	No regional lymph node disease	Yes	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2a	2 or 3 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N2b	2 or 3, at least 1 of which was clinically detected	No	IIIC	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2c	1 clinically occult or clinically detected	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC
N3a	≥4 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3b	≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes	No	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3c	≥2 clinically occult or clinically detected and/or presence of any number of matted nodes	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID

T0 — no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma); **Tis** — melanoma in situ;
Tx — thickness cannot be assessed. (Tis and Tx are not included in the table but are part of the staging system.)
Nx — Regional nodes not assessed (e.g., SLN biopsy not performed, regional nodes previously removed for another reason).
Exception: pathological N category is not required for T1 melanomas, use clinical N information. (If an SLNB was performed, the results can and *should* be used for pathological evaluation.)

T Category								
T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
No evidence of primary tumor	<0.8 mm without ulceration	<0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration	>1.0-2.0 mm without ulceration	>1.0-2.0 mm with ulceration	>2.0-4.0 mm without ulceration	>2.0-4.0 mm with ulceration	>4.0 mm without ulceration	>4.0 mm with ulceration



N Category	Number of tumor-involved regional lymph nodes	Presence of in-transit, satellite and/or microsatellite metastases
N0	No regional metastases detected	No
N1a	1 clinically occult (i.e., detected by SLN biopsy)	No
N1b	1 clinically detected	No
N1c	No regional lymph node disease	Yes
N2a	2 or 3 clinically occult (i.e., detected by SLN biopsy)	No
N2b	2 or 3, at least 1 of which was clinically detected	No
N2c	1 clinically occult or clinically detected	Yes
N3a	≥4 clinically occult (i.e., detected by SLN biopsy)	No
N3b	≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes	No
N3c	≥2 clinically occult or clinically detected and/or presence of any number of matted nodes	Yes




Melanoma-Specific Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.0
1
2
3
4
5
6
7
8
9
10
Years Since Diagnosis
N 5-YR 10-YR
IA 5225 99% 98%
IB 5749 97% 94%
IIA 2338 94% 88%
IIB 1688 87% 82%
IIC 691 82% 75%


Melanoma-Specific Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
0
2
4
6
8
10
Years Since Diagnosis
N 5-YR 10-YR
IIIA 1006 93% 88%
IIIB 1170 83% 77%
IIIC 2201 69% 60%
IIID 205 32% 24%

M Staging

- What is needed for melanoma M staging?
  - Anatomy involved
  - Don’t forget LDH

M Category	M Criteria	
	Anatomic site	LDH level
M0	No evidence of distant metastasis	Not applicable
M1	Evidence of distant metastasis	See below
M1a	Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node	Not recorded or unspecified
M1a(0)		Not elevated
M1a(1)		Elevated
M1b	Distant metastasis to lung with or without M1a sites of disease	Not recorded or unspecified
M1b(0)		Not elevated
M1b(1)		Elevated
M1c	Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease	Not recorded or unspecified
M1c(0)		Not elevated
M1c(1)		Elevated
M1d	Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease	Not recorded or unspecified
M1d(0)		Normal
M1d(1)		Elevated

Suffixes for M category: (0) LDH not elevated, (1) LDH elevated.
No suffix is used if LDH is not recorded or is unspecified.

Pathological subtypes

- Superficial spreading (70%), worst prognosis
- Lentigo maligna (insitu – freckle), lentigo maligna melanoma (invasive)
  - 10% LN positive, 5y OS 85% WLE alone
- Acral lentiginous
  - Increased in dark skinned, palms, soles
- Nodular (no radial growth)
- Desmoplastic
  - Older, more PNI, increased LR, decreased LN
- Mucosal melanoma (1%)

Presentation

- 5% with DM at diagnosis
  - 33% of these with unknown primary
- 85% with localized disease
- 10% present with regional disease

Workup

- Stage I-II
  - Imaging only to evaluate specific symptoms
- Stage III
  - SLN+ consider baseline imaging
  - cN+ or intransit, local and distant imaging
- SLNB if:
  - >0.75mm
  - Consider if ulceration, LVSI, and/or mitotic rate >=1mm2
- Clinical LN exam has 20% discordance

NCCN Margins

PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA

Tumor Thickness	Recommended Clinical Margins[b]
In situ[a]	0.5–1.0 cm
≤1.0 mm	1.0 cm (category 1)
>1.0–2 mm	1–2 cm (category 1)
>2.0–4 mm	2.0 cm (category 1)
>4 mm	2.0 cm (category 1)

- Margins may be modified to accommodate individual anatomic or functional considerations.
- Consider histologic margin assessment prior to reconstruction and closure.

Treatment of locally advanced melanoma

- Care pathways complex, evolving as evidence for systemic therapy advances
- High-dose interferon-α x1 year after resection for high risk melanoma
  - Stages IIB, IIC, III
  - Many trials – ECOG 1684/1690/1694
- Adjuvant ipilumumab in stage III disease (EORTC 18071)

Post-hoc meta-analysis of EORTC 18952 18991, Eggermont et al, 2012



Stage IIb/III-N1: HR 0·58 (99% CI 0·40–0 · 86), p=0·0003.
Stage III-N2: HR 0·89 (99% CI 0·62 to –1· 28), p=0·41.

EORTC 18071 – Long term followup, Eggermont et al, 2019



Adjuvant RT

- **TROG 02.01** (Burmeister Lancet ‘12, Henderson ‘15)
  - Palpable LND +- ISRT 48 Gy / 20 fr (margin+ 51 Gy/21)
  - SLNB not allowed
  - Nonmetastatic palpable LN at dx or at LN relapse
  - 1 parotid, 2 neck, 2 axilla, 3 groin, >=3cm neck, >=4cm axillary/inguinal
    - **“1,22,33,4”**
  - <5% of patients got adjuvant interferon

TROG 02.01



Figure 2: **Cumulative incidence curves of lymph-node field relapse as a site of first relapse (competing risks: other relapse and death)**



Figure 3: **Overall survival of eligible patients**

Adjuvant RT indications

- Burmeister criteria
- Usually in nodal recurrences, given no survival differences
- No randomized controlled trial of adjuvant immunotherapy vs RT
- Also consider ECE, >4mm esp if ulcerated or with satellitosis, and SLNB+ without completion dissection

Hypofractionation – 30 Gy / 5 2-3x/week

- Several phase II studies, retrospective
  - MDACC – Ang IJROBP ‘94, Ballo Cancer ’06
- UF 60Gy /30 vs 30 Gy/ 5
  - Chang IJROBP ‘09

- Bottom line
  - Probably equally as efficacious as moderate hypo or standard frac
  - Late toxicity a bit worse, cosmesis worse

Definitive RT

- a/b ratio ~ 0.4-2.5
- Retrospective data showed increasing efficacy with fraction size
  - Lead to RTOG 8305 – definitive palliation of 32 Gy/4 fr vs 50 Gy / 20
    - No difference in LR< 32 Gy toxic with G4 toxicity
    - CR ~ 25%
- 50-55Gy/20 daily
- 42 Gy – 54 Gy / 6 biweekly

NCCN - Metastatic Disease



Metastatic disease

- Ipilimumab – CTLA4 antibody
  - Improves OS
- Vemurafenib, Dabrafenib (BRAF inhibitors, V600 mutation)
- IL-2
- Imatinib (C-kit)

NB: Abscopal effect

- First described clinical complete response for pathologically involved neck lymph nodes second to recurrent erysipelas in 1891, reported in 1914 by William B Coley
- Radiation therapy apt to induce abscopal in melanoma, albeit rare
  - Perhaps more likely in patients treated with immunotx
  - Perhaps more likely with ablative or high dose/fraction treatments



Non-Melanoma Skin Cancers

SCC and BCC

Epidemiology – Geographic Variation



Figure 4. Lifetime risk for developing basal cell carcinoma in males (BCC[M]) and females (BCC[F]) and Squamous Cell Carcinoma in males (SCC[M]) and females (SCC[F]) in Manitoba, British Columbia, Alberta, New Brunswick, and the US.

SCC and BCC Risk Factors

- Older age
- Higher UV exposure (UVB > UVA)
- Skin type
- Prior RT exposure
- Chronic inflammation (SCC>BCC)
- Chemical exposure
- Immune deficiency
  - Transplant
  - SLL/CLL

BCC, SCC Genetics

Gorlin syndrome

- (basal cell nevus syndrome, PTCHmt)
- Autosomal dominant
- Multiple BCCs, RMS, medulloblastoma, fibrosarcomas, palmar/plantar pits, frontal bossing, bifid ribs, bone cysts
- Classically, avoid irradiating these patients





Bazex-Dupre-Christol syndrome

- X-linked, dominant
- Multiple BCC and pitting ‘ice pick’ scars on the skin



Xeroderma pigmentosum

- Xeroderma pigmentosum:
  - X-linked
  - Increased sensitivity to UV radiation
  - 1000 increased risk of skin cancer (~57% lifetime risk)
  - Faulty NER repair



- Albinisim
  - 35% lifetime risk of skin cancer
- Muir-Torre syndrome
  - Autosomal dominant
  - Sebaceous skin tumours, eyelid, GI/GU malignancies
  - Associated with MSH-1 and MLH-1 (DNA MMR genes)



Muir-Torre syndrome

BCC Genetics

- >90% associated with abnormal hedgehog pathway signaling
- Vismodegib acts on the Sonic Hedgehog Pathway (SHH)

BCC Pathologies

- Nodular (60%) – papule
- Superficial (30%) – scaly macule
- Morpheaform (5-10%)
  - More likely to have infiltrating growth
- Infiltrative, Basoquamous (rare)
  - More aggressive, behave more similar to SCC

BCC Natural History

- Locally aggressive
- 0.1% PNI
  - CN V, VII most likely
- <1% metastasize

SCC Pathologies

- SCC in Situ – Bowen’s disease
- Superficial
- Spindle cell

SCC Natural history

- Actinic Keratosis is premalignant lesion
  - 6-10% of invasive SCC in 10 years if multiple AK's
- PNI ~10%
- ~5% metastases
  - P16 positive in ~1/3 but not prognostic

SCC Lymph Node Risk

- G1
  - LN~1%
- G3, >3cm, DOI >4mm, lips, and temporal lesions
  - LN~15%
- Originating in burn scar or osteomyelitis
  - LN~30%

SCC Distant Risk

- Brantsch Lan Onc ‘08
  - Prospective series
  - 615 patients, MFU ~4y
- Increased tumor thickness >6mm
- Immunosuppresion
- Location on the ear (up to 10% DM)
- Increased tumor diameter
  - <2cm, DM 1.9%
  - >2cm DM 7.5%
  - >5cm, DM 20%



TABLE 17.3: AJCC 8th ed. (2017) Staging System for Cutaneous Squamous Cell Carcinoma

T/M \ N		cN0	cN1	cN2a	cN2b	cN2c	cN3a	cN3b
T1	• <2 cm	**I**	**III**	**IVA**				
T2	• 2.1–4 cm	**II**						
T3	• >4 cm • 1 high risk feature[1]							
T4a	• Gross cortical bone	**IVA**						
T4b	• Invasion into skull base	**IVB**						
M1	• Distant metastasis	**IVC**						

Notes: 1 high risk feature[1] = Minor bone erosion, PNI (nerve measuring ≥0.1 mm), or deep invasion (beyond subcutaneous fat or >6 mm depth). Nodal category definition is similar to other non-HPV-associated head and neck cancers; see Table 10.4 for clinical and pathologic nodal categories.

TABLE 17.4: Brigham and Women's Hospital Staging System for Cutaneous Squamous Cell Carcinoma				
		10-yr LR		**High-Risk Factors**
T1	0 High-risk factors	0.6%		Tumor ≥2 cm
T2a	1 High-risk factor	5%		Poor differentiation
T2b	2–3 High-risk factors	21%		PNI ≥0.1 mm
T3	≥4 High-risk factors	67%		Tumor beyond fat (bone invasion automatically T3)

Prognosis - Karia, JCO 2014



Comparing Modalities

Technique	Low risk LC	High Risk LC
Surgical excision with post operative margin assessment	90-95%	83-88%
Mohs	99%	90-94%
RT	90-96%	80-88%

More details in recent metaanalysis - Lee et al, Cancer 2020

ASTRO Guidelines – Likhacheva, PRO 2019

Key questions and recommendations:

- Indications for definitive RT
- Indications for postoperative RT
- Indications for treating regional nodes and regional disease management
- Radiation techniques and dose-fractionation schedules for primary site management
- Use of chemotherapy, biologic, and immunotherapy agents before, during, or after RT

Table 4. Recommendations for definitive RT

KQ1 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
1. In patients with BCC and cSCC who cannot undergo or decline surgical resection, definitive RT is recommended as a curative treatment modality.	Strong	Moderate [3-8]
2. In patients with BCC and cSCC in anatomical locations where surgery can compromise function or cosmesis, definitive RT is conditionally recommended as a curative treatment modality.	Conditional	Moderate [9-11]
3. Definitive RT for BCC and cSCC is conditionally **not** recommended in patients with genetic diseases predisposing to heightened radiosensitivity.	Conditional	Expert Opinion

Abbreviations: BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; RT = radiation therapy.

Definitive RT

- Central lesions >5mm
  - Nasal ala
  - Eyelids
  - Tip of nose
  - Lip commissure
- Lesions >2cm
  - Forehead
  - Scalp

- (relative) contraindications
  - Poor blood supply or high trauma
    - Dorsum of hand
    - Belt line
    - Shin
  - Previous RT to area
  - Exposed cartilage/bone
  - Gorlin syndrome
  - XP

Table 5. Recommendations for PORT

KQ2 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
Both BCC and cSCC		
1. PORT is recommended for gross perineural spread that is clinically or radiologically apparent.	Strong	Moderate [29,33-36]
cSCC		
2. PORT is recommended for patients with cSCC having close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome).	Strong	Low [37]
3. PORT is recommended for patients with cSCC in the setting of recurrence after a prior margin-negative resection.	Strong	Moderate [38-43]
4. In patients with cSCC, PORT is recommended for T3 and T4 tumors.*	Strong	Moderate [44-46]
5. In patients with cSCC, PORT is recommended for desmoplastic† or infiltrative tumors in the setting of chronic immunosuppression.	Strong	Moderate [44,46]
BCC		
6. PORT is conditionally recommended in patients with BCC with close or positive margins that cannot be corrected with further surgery (secondary to morbidity or adverse cosmetic outcome).	Conditional	Low [8,24]
7. PORT is conditionally recommended in patients with BCC in the setting of recurrence after a prior margin-negative resection.	Conditional	Low [8,24,47,48]
8. PORT is conditionally recommended in patients with BCC with locally advanced or neglected tumors involving bone or infiltrating into muscle.	Conditional	Low [8,24,45]

Abbreviations: BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma; KQ = key question; PORT = postoperative radiation therapy; RT = radiation therapy.

* American Joint Committee on Cancer staging table, eighth edition.[2]

† The presence of desmoplasia on light microscopy is defined as fine branches of tumor cells at the periphery and a surrounding stromal reaction. All cSCC in which at least one-third of the representative tumor specimen meet these criteria is classified as desmoplastic cSCC. One study reported findings that perineural or perivascular invasion were always associated with desmoplasia.[46]

Indications for Adjuvant RT

- Primary
  - Margin+
  - Extensive PNI
    - >0.1=mm nerve or widespread/multiple involvement
  - pT3-4
  - SCC mets to parotid
- Nodes
  - ECE
    - Can consider surveillance in pN2a so longa s ECE not present
  - ENI if recurrent after surgery
  - G3, >3cm, and/or large infiltrative-ulcerative SqCC
  - Parotid coverage (if intact) for post op face
  - 2cm margin for post op scalp lesion (Wojckicka RTO ‘09)

Table 7. Recommendations for radiation techniques and dose-fractionation schedules for primary site management

KQ4 Recommendations	Strength of Recommendation	Quality of Evidence (Refs)
1. In patients with BCC and cSCC receiving RT in the definitive setting, the following dose-fractionation schemes* are recommended: ○ Conventional (180–200 cGy/fx): BED_{10} 70–93.5 ○ Hypofractionation (210–500 cGy/fx): BED_{10} 56–88 **Implementation Remark**: Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week.	Strong	Low 10,79,80,82,88-94
2. In patients with BCC and cSCC receiving RT in the postoperative setting, the following dose-fractionation schemes* are recommended: ○ Conventional (180–200 cGy/fx): BED_{10} 59.5–79.2 ○ Hypofractionation (210-500 cGy/fx): BED_{10} 56–70.2 **Implementation Remark:** Conventional fractionation is delivered 5 days per week; hypofractionation is delivered daily or 2-4 times per week.	Strong	Low 5,48,90,93,95-100

Abbreviations: BCC = basal cell carcinoma; BED_{10} = biologically effective dose assuming an $\alpha/\beta = 10$; cSCC = cutaneous squamous cell carcinoma; fx = fraction; KQ = key question; RT = radiation therapy.

* See Table 8 with specific fractionation schemes.

Figure 2. Dose fractionation summary

Dose (cGy) \ # of Fractions	8	9	10	11	14	15	16	17	18	20	28	30	33	35	36
180											5040		5940		6480
200												6000	6600	7000	
250										5000					
275										5500					
300					4200	4500	4800	5100	5400						
340									6120						
400				4400											
440			4400												
450		4050	4500												
500	4000														

Dosing – UK Survey, McPartlin, BJR 2014

Table 1. Popularity of commonly suggested dose fractionations

Dose fractionation	Number of times suggested
18 Gy/1#	41
20 Gy/1#	18
32 Gy/5#	27
35 Gy/5#	237
40.5 Gy/9#	22
40 Gy/10#	29
45 Gy/10#	170
45 Gy/9#	51
45 Gy/15#	15
50 Gy/15#	56
50 Gy/20#	57
55 Gy/20#	134
60 Gy/30#	26
66 Gy/33#	11
27 Gy/3# over 2 weeks	20
28 Gy/2# over 6 weeks	11
38 Gy/6# over 6 weeks	11
45 Gy/9# over 3 weeks	24

Figure 1. Fractionation regimes employed for a given scenario in different patient groups. BCC, basal cell carcinomas; SCC, squamous cell carcinomas.



Figure 2. Radiation modality employed for given scenario in different patient groups. BCC, basal cell carcinomas; kv, kilovoltage; SCC, squamous cell carcinomas.



How to choose?

- Can only treat with what you have available
- If you have choice, is a balance between
  - Practicality
  - Resources
  - Toxicity/Anatomy
- Need to know both orthovoltage and electrons well for your exams

Post operative head and neck guidelines – IJROBP 2020

Clinical Investigation

Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Sandro V. Porceddu, MBBS, FRANZCR, MD,[*,†] Christopher Daniels, MBBS, FRANZCR,[*] Sue S. Yom, MD, PhD,[‡] Howard Liu, MBBS, FRANZCR,[*,†] John Waldron, MD, FRCPC, MSc,[§,‖] Vincent Gregoire, MD, PhD,[¶] Alisha Moore, BMedRadSci(RT),[#,**] Michael Veness, MBBS, MD, MMed (Clin Epi), FRANZCR,[††,‡‡] Min Yao, MD, PhD,[§§] Jorgen Johansen, MD, PhD,[‖‖] Hisham Mehanna, PhD, BMedSc, MB ChB, FRCS, FRCS (ORL-HNS),[¶¶] Danny Rischin, MBBS, FRACP, MD,[##,***] and Quynh-Thu Le, MD[†††]

*Princess Alexandra Hospital, Brisbane, Australia; [†]University of Queensland, Queensland, Australia; [‡]University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California; [§]Princess Margaret Cancer Centre, Toronto, Canada; [‖]University of Toronto, Toronto, Canada; [¶]Centre Leon Berard, Lyon, France; [#]Trans Tasman Radiation Oncology Group, Newcastle, Australia; **University of Newcastle, Newcastle, Australia; [††]Westmead Hospital, Westmead, Australia; [‡‡]University of Sydney, Sydney, Australia; [§§]Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, Ohio; [‖‖]Odense University Hospital, Denmark; [¶¶]University of Birmingham, United Kingdom; [##]Peter MacCallum Cancer Center,

Post Operative Volumes

Table 1 Summary of target volume definitions

Target volume	Structure	Definition
Site of primary tumor before excision*	HRTVp	The volume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings
Site of involved lymph nodes before excision*	HRTVn	The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings
Subsite of the HRTVp likely to carry a higher burden of microscopic disease (ie, positive or margin clearance <2 mm) and warranting a boost dose	HRTVp_Boost	The subvolume that represents the preoperative primary site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk
Subsite of the HRTVn disease likely to carry a higher burden of microscopic disease (ie, positive margin or extranodal extension)	HRTVn_Boost	The volume that represents the preoperative regional nodal site GTV transposed onto the planning CT imaging data set and modified to account for postoperative anatomic changes and pathologic findings and considered at particularly high risk
Primary site high-risk clinical target volume	CTVp_HR	Minimum volume includes HRTVp + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire operative bed, reconstruction flap, or graft site. Resected LNPNS
Nodal site high-risk clinical target volume	CTVn_HR	Minimum volume includes HRTVn + 5 mm isotropic expansion and modified to anatomic barriers. May also include the entire involved neck node level/basin or neck dissection/parotidectomy bed
Primary site lesser risk clinical target volume	CTVp_LR	The primary site operative bed that does not meet the criteria for CTVp_HR and modified to anatomic barriers. May also include the broader operative bed, reconstruction flap, or graft site. For LNPNS it also includes the undissected zone proximal to the involved zone
Nodal site lesser risk clinical target volume	CTVn_LR	The nodal dissection operative bed that does not meet the criteria for CTVn_HR, modified to anatomic barriers, and next echelon of surgically undisrupted clinically uninvolved nodes (elective)
Primary tumor boost site (optional)	CTVp_HR_Boost	Minimum volume includes HRTVp_Boost + 5 mm expansion and modified to anatomic barriers
Nodal site boost site (optional)	CTVn_HR_Boost	Minimum volume includes HRTVn_Boost + 5 mm expansion and modified to anatomic barriers

Abbreviations: CT = computed tomography; CTV = clinical target volume; GTV = gross tumor volume; HR = high risk; HRTV = high-risk tumor volume; LNPNS = large nerve perineural spread; LR = low risk; n = nodal; p = primary.

* Where there is substantial overlap of the HRTVp and HRTVn, a single HRTV termed HRTVp/n may be used (eg, an extensive primary lesion over the preauricular area with underlying intraparotid nodal metastases).

Post Operative Doses

Table 2 Summary of recommended minimum prescribed doses*

Target volume	IMRT technique	Non-IMRT technique
PTVp_HR and/or PTVn_HR	60.0 Gy in 30 fractions	60.0 Gy in 30 fractions
PTVp_LR and/or PTVn_LR	56.0 Gy in 30 fractions Optional: 54.0 Gy in 30 fractions for surgically undisrupted LR region	54.0 Gy in 27 fractions Optional: 50.0 Gy in 25 fractions for surgically undisrupted LR region
PTVp_boost and/or PTVn_boost (optional)	66.0 Gy in 33 fractions or 63.0 Gy in 30 fractions	66.0 Gy in 33 fractions

Abbreviations: HR = high risk; IMRT = intensity modulated radiation therapy; LR = lesser risk; n = nodal involvement; p = primary site; PTV = planning target volume.

* Fractionation schedules are described as once daily at 5 fractions per week.

Variance exists, and ok to use SIB with slight hypofraction at RO's discretion (ie 63-66Gy/ 30 fr) – see last line

Treatment Planning Considerations

CTV Margins

- BCC
  - Well defined, <2cm
    - 0.5-**1.0cm**
  - >2cm
    - 1-**1.5cm**
  - Use the larger CTV for infiltrative, poorly defined histologies
  - 0.5cm depth, 0.25 if mobile, thin skin
- SCC
  - Well defined, <2cm
    - 1.1cm
  - High risk features, >2cm
    - 1-**1.5cm**
  - Min 0.5cm depth

Need to tailor to patient, anatomy, technique, and fractionation!

IJROBP Khan et al 2011

Rad & Onc Khan et al 2012

What about PTV?

- PTV/penumbra depends on technique
- IMRT
  - PTV +3-5mm depending on setup, IGRT
- ICRU model breaks down somewhat for clinical setups
- Electrons
  - +5-10mm for penumbra
- Orthovoltage
  - PTV/Penumbra 2-3mm, though often collimated to CTV

Orthovoltage	Electrons
Advantages: • Better beam flatness • Sharper penumbra • Maximum dose at skin • Smaller margin • Smaller fields • No bolus	**Advantages:** • No F – factor • Greater depth dose with appropriate energy to treat large or thick lesions • Can have sharper fall off/less exit dose than orthovoltage if prescribed appropriately
Disadvantages: • High bone absorption (F-factor/photo electric effect) • Limited penetration/not ideal for thick or deep lesions	**Disadvantages:** • Dosimetry may be more complex • Skin sparing effect, need bolus for surface dose at lower energies • Larger field size • Electron back scatter

Stand-off correction factor



Fig 16.3 (a) Positive stand-off of 0.5 cm between lesion and applicator. (b) Negative stand-off of 0.5 cm.

Case 1 – BCC of Anterior Pinna



- 1cm margin around full thickness of pinna
- 5cm circle applicator
- 150 kV photons
- HVL 6mm Al
- Shield behind ear
- 50 Gy / 20

Case 2 – BCC of Nasal Ala



- 1cm margin around full thickness of pinna
- 5cm circle applicator
- 150 kV photons
- HVL 6mm Al
- 50 Gy / 20
- Shield in left nostril to protect nasal septum
- Consider shield in upper gum, eye

Case 3 - SCC of Preauricular skin



- Electrons modality of choice
  - Spares brain
- Tissue equivalent plug into ear canal to reduce funneling of dose into eardrum and middle ear
- 12 MeV + 0.5cm bolus to 90%
- 66 Gy in 30 fractions
  - RBE is ~0.9

Merkel Cell Carcinoma

Merkel Cell Carcinoma - Rare

- Rare - ~0.6/100 000 people/ year
- Canada – estimated 290 diagnoses/year

Merkel Cell Carcinoma Genetics

- Merkel cell polyomavirus (MCV) detected in >80%
- MCV viral proteins bind to RB, interfering with TP53
- MCV neg – UV induced mutational inactivation of p53 and Tb, more mutations (prognosis ?worse)
- CK20- associated with MCV

Merkel Cell Histology

- Cell of origin thought to be epidermal or dermal cell, rather than differentiated Merkel cell
  - ie not a tactile neuroendocrine epithelial cell (aka touch cell)
- One of those small round blue cell tumors



Merkel Cell Presentation

- Rapidly enlarging, painless, red denuded nodule
- 65% local dz
- 25% regional
- 10% DM
- 20% have occult LN involvement, even if <2cm primary
- Ultimately DM in 50-60%
- Need PET staging and followup



TABLE 19.2: AJCC 8th ed. (2017) Staging for Merkel Cell Carcinoma[6]

<table>
<tr><th colspan="2">T/M \ N</th><th>cN0</th><th>cN1</th><th>pN1a(sn)</th><th>pN1a</th><th>pN1b</th><th>c/pN2</th><th>c/pN3</th></tr>
<tr><td>T1</td><td>• ≤2 cm</td><td>I</td><td colspan="4" rowspan="4">IIIA</td><td colspan="3" rowspan="4">IIIB</td></tr>
<tr><td>T2</td><td>• 2.1–5 cm</td><td rowspan="2">IIA</td></tr>
<tr><td>T3</td><td>• >5 cm</td></tr>
<tr><td>T4</td><td>• Invasion[1]</td><td>IIB</td></tr>
<tr><td>M1a</td><td>• Distant skin
• Subcutaneous tissue
• Distant LN</td><td colspan="7" rowspan="3">IV</td></tr>
<tr><td>M1b</td><td>• Lung</td></tr>
<tr><td>M1c</td><td>• Any other visceral sites</td></tr>
</table>

Major changes in the AJCC 8th Edition include delineation between clinical & pathologic N categories, new N2-N3 categories and updates to the prognostic staging groups.

Notes: Invasion[1] = Invasion into fascia, cartilage, bone, or muscle.

cN1, metastasis in regional LN(s); pN1a(sn), clinically occult regional LN identified by sentinel lymph node biopsy only; pN1a, clinically occult regional LN following lymph node dissection; pN1b, clinically and/or radiologically detected regional LN with microscopic confirmation; c/pN2, in-transit metastasis (discontinuous from primary tumor, located between primary tumor and draining lymph node basin), without LN metastasis; c/pN3, in-transit metastasis with LN metastasis.

Treatment

- WLE with 1-2cm margin
  - cN+ -> FNA
  - cN(-) -> SLNB
- LC 40-50% with Sx alone
  - 80% with adj RT



Fig. 2. Forrest plot for overall survival analysis.

Adjuvant RT

- Recurrences recur early
  - Treat early, ideally w/in 4-6 weeks
- Could consider observation:
  - <1-2cm, widely excised, no LVI, not immunosuppressed

Risk factors for recurrence

- Thickness/DOI
- LVSI
- Infiltrative growth
- SLN status

Treatment planning

- Cutaneous Oncology Group of French Society of Dermatology Guidelines (Boccara Eur J Derm 2012)
  - 50 Gy + 3cm margins +10 Gy boost to tumor bed
- CTV at least >=2cm in H&N
- CTV = 3-5cm elsewhere

- R0: 50-56 Gy
- R1: 56- 60 Gy
- R2 or gross nodes 60-66 Gy
- cN0 without nodal evaluation
  - 45 – 50 Gy
- Coverage of LNs for SLNB(-) or LND(-) is controversial

Prognosis – Song, ASO 2020

- 50% stage I, 36% stage III
- MFU 3y
- Regional or DM in ~60%



FIG. 4 Kaplan–Meier estimates of Merkel cell-specific survival

Surface Anatomy – Dunn et al, British Journal of Plastic Surgery 1997



Fig. 1


7
14
6
13
5
11
8
10
1
9
12
3
4
18
2
5
6
15
16
17


20
16
21
17
22
18
28
25
24
27
23
19
26
8
7
F7
1
10
13
11
14
12
6
4
15
5
14
F10
2


8
16
17
13
18
14
19
12
11
20
1
2
3
15
9
23
4
21
10
22
5
6
24
7
8



Good luck everyone
Stay safe

jordan.stosky@ahs.ca